General description

A cell-permeable plant-derived pentacyclic triterpene acid that displays anti-inflammatory, immunomodulatory, and antitumor activities. Shown to inhibit the phosphatase activity of SHP2, PTP1B, and TCPTP (IC₅₀ = 2.73, 3.08 and 3.33 µM, respectively) as well as induce IR autophosphorylation independent of its phosphatase inhibitory activity. Ursolic acid is also reported to inhibit NF-κB and STAT3 pathway activation in cancer cultures, resulting in enhanced sensitivity to chemotherapy agents and apoptotic cell death.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Li, Y., et al. 2010. Int. J. Cancer127, 462.Pathak, A.K., et al. 2007. Mol. Cancer Res.5, 943.Jung, S.H., et al. 2007. Biochem. J.403, 243.Zhang, W., et al. 2006. Biochim. Biophys. Acta1760, 1505.Shishodia, S., et al. 2003. Cancer Res.63, 4375.

Packaging

Packaged under inert gas

50 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)